➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Medtronic
Mallinckrodt
McKesson
McKinsey

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Neuropeptide Y


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Neuropeptide Y?

Neuropeptide Y is an investigational drug.

There have been 4 clinical trials for Neuropeptide Y. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, and Disease. The leading clinical trial sponsors are Westchester Medical Center, U.S. Army Medical Research and Development Command, and Vanderbilt University.

There are two hundred and sixty-two US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Neuropeptide Y
TitleSponsorPhase
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress DisorderU.S. Army Medical Research and Development CommandPhase 1/Phase 2
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress DisorderWestchester Medical CenterPhase 1/Phase 2
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress DisorderNew York Medical CollegePhase 1/Phase 2

See all Neuropeptide Y clinical trials

Clinical Trial Summary for Neuropeptide Y

Top disease conditions for Neuropeptide Y
Top clinical trial sponsors for Neuropeptide Y

See all Neuropeptide Y clinical trials

US Patents for Neuropeptide Y

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Neuropeptide Y   Start Trial Neuropeptide Y-derived peptides University of Copenhagen (Copenhagen K, DK) N.ae butted.stved Hospital (N.ae butted.stved, DK)   Start Trial
Neuropeptide Y   Start Trial Methods for the treatment of kidney fibrosis THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, MA)   Start Trial
Neuropeptide Y   Start Trial Method using an Y1 receptor activator for treating an anticancer agent-induced nephrotoxic injury KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR)   Start Trial
Neuropeptide Y   Start Trial Diagnostic method for diagnosing depression and monitoring therapy effectiveness BRAINLABS B.V. (NL) RIJKSUNIVERSITEIT GRONINGEN (NL) ACADEMISCH ZIEKENHUIS GRONINGEN (NL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Neuropeptide Y

Drugname Country Document Number Estimated Expiration Related US Patent
Neuropeptide Y Denmark 2983690 2033-04-10   Start Trial
Neuropeptide Y European Patent Office 2983690 2033-04-10   Start Trial
Neuropeptide Y Spain 2729970 2033-04-10   Start Trial
Neuropeptide Y Poland 2983690 2033-04-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Harvard Business School
McKesson
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.